Translating Molecules into Medicines Cross-Functional Integration at the Drug Discovery-Development Interface
Language: English
Published by Springer, 2017
Series: Book 24 of 38 - AAPS Advances in the Pharmaceutical Sciences
- Hardcover
- New

Condition: New
US$ 423.20
Quantity: 2 available
Add to basketItem description from seller
Tackling translational medicine with a focus on the drug discovery development-interface, this book integrates approaches and tactics from multiple disciplines, rather than just the pharmaceutical aspect of the field. The authors of each chapter address the paradox between the molecular understanding of diseases, drug discovery, and drug development. Laying out the detailed trends from various fields, different chapters are dedicated to target engagement, toxicological safety assessments, and the compelling relationship of optimizing early clinical studies with design strategies. The book also highlights the importance of balancing the three pillars: sufficient efficacy, acceptable safety and appropriate pharmacokinetics, all of which are crucial to successful efforts in discovery and development. With discussions regarding the combined approaches of molecular research, personalized medicine, pre-clinical and clinical development, as well as targeted therapies-this compendium is a flexible fit, perfect for professionals in the pharmaceutical industry and related academic fields. Sprache: Englisch Gewicht in Gramm: 841.…
Seller Inventory # IB-638615
- Title
- Translating Molecules into Medicines Cross-Functional Integration at the Drug Discovery-Development Interface
- Publisher
- Springer
- Publication year
- 2017
- Condition
- Neu
- Binding
- Gebundene Ausgabe
- Language
- English
- ISBN 10
- 3319500406
- ISBN 13
- 9783319500409
- Item weight
- 841 grams
- Series
- Book 24 of 38: AAPS Advances in the Pharmaceutical Sciences
"Synopsis" may belong to another edition of this title.
About the Author
David M. Bender is a Senior Research Scientist in Small Molecule Design and Development at Eli Lilly and Co. He received a B.S in chemistry from Miami University and an M.S. in organic chemistry from Colorado State University where he conducted research into the design and synthesis of novel antibacterial agents. He joined Eli Lilly and Co. in 1998 as a synthetic organic chemist in Discovery Chemistry Research. In 2009, he joined the Product Research and Development organization, where he has focused on formulation development, small molecule developability, absorption modeling and alternate drug delivery. Mr. Bender is currently a group leader in the Product Design and Developability group, and is responsible for overseeing the design and manufacture of clinical drug product for small molecules entering Lilly’s development pipeline.
Daniel R. Mudra is Director of ADME at Eli Lilly and Company. He earned his B.S. from The University of Dayton studying pharmacokinetic/pharmacodynamic effects of drug-impregnated implants and an M.S. from Loyola University Chicago investigating the biochemical regulation of the p38 kinase pathway. He earned his doctorate in Pharmaceutical Chemistry from The University of Kansas developing in situ and computational models of absorption studying the effects of excipients on permeability, metabolism and transport. Dr. Mudra began his industrial research career at XenoTech, LLC and has published on models of P450 induction and inhibition, drug absorption and PK. Since joining Lilly, he has contributed to projects from target identification to clinical development across a variety of therapeutic areas. He leads in the incorporation of mechanistic and physiologically based PK modeling including the use of molecular attributes to predict human clearance pathways.
"About the title" may belong to another edition of this title.
Shipping rates from Germany to U.S.A.
| Item | 10 to 12 business days | 8 to 10 business days |
|---|---|---|
| First item | US$ 54.75 | US$ 82.29 |
Payment methods
- Check